Tropicamide/phenylephrine
Combination of
TropicamideAnticholinergic
PhenylephrineAlpha-1 adrenergic receptor agonist
Clinical data
Trade namesMydcombi
Routes of
administration		Topical, ophthalmic
ATC code
Legal status
Legal status

Tropicamide/phenylephrine, sold under the brand name Mydcombi is a fixed dose combination of tropicamide and phenylephrine used to dilate the eyes (mydriasis).[1] It contains, tropicamide, an anticholinergic, and phenylephrine, as the hydrochloride, an alpha-1 adrenergic receptor agonist.[1] It is sprayed into the eyes.[1]

It was approved for medical use in the United States in May 2023.[2][3]

Medical uses

Tropicamide/phenylephrine is used for the short-term dilation of the pupils.[1]

References

  1. 1 2 3 4 5 https://mydcombi.com/wp-content/uploads/2023/05/MydCombi-PI-05072023.pdf
  2. ↑ "Mydcombi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 8 May 2023.
  3. ↑ "Eyenovia Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company's Proprietary Optejet Device Platform". Eyenovia. 8 May 2023. Retrieved 8 May 2023.
  • Clinical trial number NCT03751631 for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-1)" at ClinicalTrials.gov
  • Clinical trial number NCT03751098 for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-2)" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.